In this single-arm, phase 2, nonrandomized clinical trial of 67 patients with ERBB2-positive early breast cancer, the overall pathologic complete response rate of 6 cycles of neoadjuvant PATH regimen was 61%. The gene discussed is ERBB2; the disease is breast carcinoma.